Search

Your search keyword '"Azzollini, J"' showing total 193 results

Search Constraints

Start Over You searched for: Author "Azzollini, J" Remove constraint Author: "Azzollini, J"
193 results on '"Azzollini, J"'

Search Results

2. Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores

3. Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers

4. Expanding the clinical spectrum of the ‘HDAC8-phenotype’ – implications for molecular diagnostics, counseling and risk prediction

6. Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study

7. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers

8. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers

9. Author Correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers (Nature Communications, (2021), 12, 1, (1078), 10.1038/s41467-020-20496-3).

10. Erratum: Author Correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers (Nature communications (2021) 12 1 (1078)).

11. Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants.

12. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers.

13. Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores.

14. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers (vol 12, 1078, 2021)

15. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers.

16. Author Correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers.

17. Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses

18. Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses

19. Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes

20. Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes

21. Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses

22. Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness

23. Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants

24. The spectrum of fancm protein truncating variants in European breast cancer cases.

25. Association of genomic domains in BRCA1 and BRCA2 with prostate cancer risk and aggressiveness.

26. Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes.

27. Transcriptome-wide association study of breast cancer risk by estrogen-receptor status.

28. Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses.

29. Transcriptome-wide association study of breast cancer risk by estrogen-receptor status

30. Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses

31. Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness

32. Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants

33. Transcriptome-wide association study of breast cancer risk by estrogen-receptor status

34. The Spectrum of FANCM Protein Truncating Variants in European Breast Cancer Cases

35. Pre- and Post-Zygotic TP53 De Novo Mutations in SHH-Medulloblastoma

37. The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer

38. The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer

39. Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers

40. The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer.

41. Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer.

42. Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification.

43. Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers

44. Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer

45. Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification

46. Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer

47. Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification

48. Individuals with &ITFANCM&IT biallelic mutations do not develop Fanconi anemia, but show risk for breast cancer, chemotherapy toxicity and may display chromosome fragility

50. Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations

Catalog

Books, media, physical & digital resources